Regulatory ProspectsEnobosarm remains the front-runner in demonstrating clinical lean mass improvements in GLP1-driven lean mass loss, which could lead to regulatory discussions and potential partnerships.

Bears Say

Financial NeedsThe company may need to raise additional capital within the next 12 months, in our view.

Stock PerformanceA significant intra-day stock sell-off was attributed to the lack of meaningful weight loss benefits observed during the initial period of the study.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

10.56% Insiders

6.58% Mutual Funds

9.25% Other Institutional Investors

63.54% Public Companies and Individual Investors

Detailed Ownership Overview >

VERU FAQ

What was Veru’s price range in the past 12 months?

Veru lowest stock price was $0.45 and its highest was $1.42 in the past 12 months.

What is Veru’s market cap?

Veru’s market cap is $101.88M.

When is Veru’s upcoming earnings report date?

Veru’s upcoming earnings report date is Aug 07, 2025 which is in 40 days.

How were Veru’s earnings last quarter?

Veru released its earnings results on May 08, 2025. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.062 by $0.012.

Is Veru overvalued?

According to Wall Street analysts Veru’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Veru pay dividends?

Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here

What is Veru’s EPS estimate?

Veru’s EPS estimate is -0.05.

How many shares outstanding does Veru have?

Veru has 146,583,920 shares outstanding.

What happened to Veru’s price movement after its last earnings report?

Veru reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.062. Following the earnings report the stock price went up 4%.

Which hedge fund is a major shareholder of Veru?

Currently, no hedge funds are holding shares in VERU

Veru Stock Smart Score

Neutral

Fundamentals

Return on Equity

-88.03%

Trailing 12-Months

Asset Growth

-54.50%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Veru

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call presented several positive developments, such as successful Phase 2b study results for enobosarm and financial improvements in net loss from continuing operations. However, the company faces challenges with increased R&D costs, a significant decrease in cash reserves, and a net loss on the sale of the FC2 business. While there are promising regulatory and clinical catalysts ahead, the need for additional funding is a concern.Read More>